Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel
Journal cover image

Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma.

Publication ,  Journal Article
Gibney, GT; Hamid, O; Lutzky, J; Olszanski, AJ; Mitchell, TC; Gajewski, TF; Chmielowski, B; Hanks, BA; Zhao, Y; Newton, RC; Maleski, J ...
Published in: J Immunother Cancer
March 20, 2019

BACKGROUND: Epacadostat is a potent inhibitor of the immunosuppressive indoleamine 2,3-dioxygenase 1 (IDO1) enzyme. We present phase 1 results from a phase 1/2 clinical study of epacadostat in combination with ipilimumab, an anti-cytotoxic T-lymphocyte-associated protein 4 antibody, in advanced melanoma (NCT01604889). METHODS: Only the phase 1, open-label portion of the study was conducted, per the sponsor's decision to terminate the study early based on the changing melanoma treatment landscape favoring exploration of programmed cell death protein 1 (PD-1)/PD-ligand 1 inhibitor-based combination strategies. Such decision was not related to the safety of epacadostat plus ipilimumab. Patients received oral epacadostat (25, 50, 100, or 300 mg twice daily [BID]; 75 mg daily [50 mg AM, 25 mg PM]; or 50 mg BID intermittent [2 weeks on/1 week off]) plus intravenous ipilimumab 3 mg/kg every 3 weeks. RESULTS: Fifty patients received ≥1 dose of epacadostat. As of January 20, 2017, 2 patients completed treatment and 48 discontinued, primarily because of adverse events (AEs) and disease progression (n = 20 each). Dose-limiting toxicities occurred in 11 patients (n = 1 each with epacadostat 25 mg BID, 50 mg BID intermittent, 75 mg daily; n = 4 each with epacadostat 50 mg BID, 300 mg BID). The most common immune-related treatment-emergent AEs included rash (50%), alanine aminotransferase elevation (28%), pruritus (28%), aspartate aminotransferase elevation (24%), and hypothyroidism (10%). Among immunotherapy-naive patients (n = 39), the objective response rate was 26% by immune-related response criteria and 23% by Response Evaluation Criteria in Solid Tumors version 1.1. No objective response was seen in the 11 patients who received prior immunotherapy. Epacadostat exposure was dose proportional, with clinically significant IDO1 inhibition at doses ≥25 mg BID. CONCLUSIONS: When combined with ipilimumab, epacadostat ≤50 mg BID demonstrated clinical and pharmacologic activity and was generally well tolerated in patients with advanced melanoma. TRIAL REGISTRATION: ClinicalTrials.gov identifier, NCT01604889 . Registration date, May 9, 2012, retrospectively registered.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Immunother Cancer

DOI

EISSN

2051-1426

Publication Date

March 20, 2019

Volume

7

Issue

1

Start / End Page

80

Location

England

Related Subject Headings

  • Treatment Outcome
  • Sulfonamides
  • Oximes
  • Neoplasm Metastasis
  • Middle Aged
  • Melanoma
  • Male
  • Ipilimumab
  • Humans
  • Female
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Gibney, G. T., Hamid, O., Lutzky, J., Olszanski, A. J., Mitchell, T. C., Gajewski, T. F., … Weber, J. S. (2019). Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma. J Immunother Cancer, 7(1), 80. https://doi.org/10.1186/s40425-019-0562-8
Gibney, Geoffrey T., Omid Hamid, Jose Lutzky, Anthony J. Olszanski, Tara C. Mitchell, Thomas F. Gajewski, Bartosz Chmielowski, et al. “Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma.J Immunother Cancer 7, no. 1 (March 20, 2019): 80. https://doi.org/10.1186/s40425-019-0562-8.
Gibney GT, Hamid O, Lutzky J, Olszanski AJ, Mitchell TC, Gajewski TF, et al. Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma. J Immunother Cancer. 2019 Mar 20;7(1):80.
Gibney, Geoffrey T., et al. “Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma.J Immunother Cancer, vol. 7, no. 1, Mar. 2019, p. 80. Pubmed, doi:10.1186/s40425-019-0562-8.
Gibney GT, Hamid O, Lutzky J, Olszanski AJ, Mitchell TC, Gajewski TF, Chmielowski B, Hanks BA, Zhao Y, Newton RC, Maleski J, Leopold L, Weber JS. Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma. J Immunother Cancer. 2019 Mar 20;7(1):80.
Journal cover image

Published In

J Immunother Cancer

DOI

EISSN

2051-1426

Publication Date

March 20, 2019

Volume

7

Issue

1

Start / End Page

80

Location

England

Related Subject Headings

  • Treatment Outcome
  • Sulfonamides
  • Oximes
  • Neoplasm Metastasis
  • Middle Aged
  • Melanoma
  • Male
  • Ipilimumab
  • Humans
  • Female